Header Logo

Connection

Michael Heneka to Inflammasomes

This is a "connection" page, showing publications Michael Heneka has written about Inflammasomes.
Connection Strength

5.788
  1. Owona BA, Mary A, Messi AN, Ravichandran KA, Mbing JN, Pegnyemb E, Moundipa PF, Heneka MT. Biflavonoid Methylchamaejasmin and Khaya grandifoliola?Extract Inhibit NLRP3 Inflammasome in THP-1 Cell Model of Neuroinflammation. Mol Neurobiol. 2025 Feb; 62(2):1605-1619.
    View in: PubMed
    Score: 0.697
  2. Ravichandran KA, Heneka MT. Inflammasome activation in neurodegenerative diseases. Essays Biochem. 2021 12 22; 65(7):885-904.
    View in: PubMed
    Score: 0.583
  3. Scheiblich H, Bousset L, Schwartz S, Griep A, Latz E, Melki R, Heneka MT. Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct a-Synuclein Assemblies. J Immunol. 2021 10 15; 207(8):2143-2154.
    View in: PubMed
    Score: 0.572
  4. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, Griep A, Santarelli F, Brosseron F, Opitz S, Stunden J, Merten M, Kayed R, Golenbock DT, Blum D, Latz E, Bu?e L, Heneka MT. NLRP3 inflammasome activation drives tau pathology. Nature. 2019 11; 575(7784):669-673.
    View in: PubMed
    Score: 0.505
  5. Venegas C, Heneka MT. Inflammasome-mediated innate immunity in Alzheimer's disease. FASEB J. 2019 12; 33(12):13075-13084.
    View in: PubMed
    Score: 0.503
  6. Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci. 2018 10; 19(10):610-621.
    View in: PubMed
    Score: 0.466
  7. Scheiblich H, Schl?tter A, Golenbock DT, Latz E, Martinez-Martinez P, Heneka MT. Activation of the NLRP3 inflammasome in microglia: the role of ceramide. J Neurochem. 2017 12; 143(5):534-550.
    View in: PubMed
    Score: 0.437
  8. Heneka MT. Inflammasome activation and innate immunity in Alzheimer's disease. Brain Pathol. 2017 03; 27(2):220-222.
    View in: PubMed
    Score: 0.418
  9. McManus RM, Komes MP, Griep A, Santarelli F, Schwartz S, Ram?n Perea J, Schlachetzki JCM, Bouvier DS, Khalil MA, Lauterbach MA, Heinemann L, Schl?ter T, Pour MS, Lovotti M, Stahl R, Duthie F, Rodr?guez-Alc?zar JF, Schmidt SV, Spitzer J, Noori P, Maillo A, Boettcher A, Herron B, McConville J, Gomez-Cabrero D, Tegn?r J, Glass CK, Hiller K, Latz E, Heneka MT. NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer's disease progression. Immunity. 2025 Feb 11; 58(2):326-343.e11.
    View in: PubMed
    Score: 0.181
  10. Karabag D, Heneka MT, Ising C. The putative contribution of cellular senescence to driving tauopathies. Trends Immunol. 2024 Oct; 45(10):837-848.
    View in: PubMed
    Score: 0.176
  11. Ravichandran KA, Heneka MT. Inflammasomes in neurological disorders - mechanisms and therapeutic potential. Nat Rev Neurol. 2024 02; 20(2):67-83.
    View in: PubMed
    Score: 0.168
  12. Braatz C, Komes MP, Ravichandran KA, de Fragas MG, Griep A, Schwartz S, McManus RM, Heneka MT. NLRP3-directed antisense oligonucleotides reduce microglial immunoactivities in vitro. J Neurochem. 2024 Oct; 168(10):3467-3481.
    View in: PubMed
    Score: 0.159
  13. Jiang S, Maphis NM, Binder J, Chisholm D, Weston L, Duran W, Peterson C, Zimmerman A, Mandell MA, Jett SD, Bigio E, Geula C, Mellios N, Weick JP, Rosenberg GA, Latz E, Heneka MT, Bhaskar K. Proteopathic tau primes and activates interleukin-1? via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell Rep. 2021 09 21; 36(12):109720.
    View in: PubMed
    Score: 0.143
  14. Beyer MMS, Lonnemann N, Remus A, Latz E, Heneka MT, Korte M. Enduring Changes in Neuronal Function upon Systemic Inflammation Are NLRP3 Inflammasome Dependent. J Neurosci. 2020 07 08; 40(28):5480-5494.
    View in: PubMed
    Score: 0.131
  15. Friker LL, Scheiblich H, Hochheiser IV, Brinkschulte R, Riedel D, Latz E, Geyer M, Heneka MT. ?-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. Cell Rep. 2020 03 17; 30(11):3743-3754.e6.
    View in: PubMed
    Score: 0.129
  16. Luciunaite A, McManus RM, Jankunec M, R?cz I, Dansokho C, Dalgediene I, Schwartz S, Brosseron F, Heneka MT. Soluble A? oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J Neurochem. 2020 12; 155(6):650-661.
    View in: PubMed
    Score: 0.128
  17. Tzeng TC, Hasegawa Y, Iguchi R, Cheung A, Caffrey DR, Thatcher EJ, Mao W, Germain G, Tamburro ND, Okabe S, Heneka MT, Latz E, Futai K, Golenbock DT. Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):9002-9007.
    View in: PubMed
    Score: 0.116
  18. Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz S, Santarelli F, Kummer MP, Griep A, Gelpi E, Beilharz M, Riedel D, Golenbock DT, Geyer M, Walter J, Latz E, Heneka MT. Microglia-derived ASC specks cross-seed amyloid-? in Alzheimer's disease. Nature. 2017 12 20; 552(7685):355-361.
    View in: PubMed
    Score: 0.110
  19. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014 Jul; 14(7):463-77.
    View in: PubMed
    Score: 0.087
  20. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013 Jan 31; 493(7434):674-8.
    View in: PubMed
    Score: 0.078
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.